Skip to main content
Canna~Fangled Abstracts

Alzheimer’s disease: a study of cannabidiol targets in Alzheimer’s

By March 7, 2025No Comments

PubMed is a free, comprehensive database of scientific and medical literature, primarily focusing on biomedical and life sciences research. It is maintained by the National Library of Medicine (NLM) at the National Institutes of Health (NIH). PubMed is one of the most widely used resources for healthcare professionals, researchers, and students to access peer-reviewed articles, clinical studies, and other scientific publications.

Review
. 2024 Oct 11;8(1):1339-1360.

doi: 10.1177/25424823241284464. eCollection 2024.

A systematic study of molecular targets of cannabidiol in Alzheimer’s disease

Nil Patil 1 2, Khushalika Patil 2, Mukul Jain 1 2 3, Arifullah Mohammed 4, Alpa Yadav 5, Parmdeep Singh Dhanda 6, Chittaranjan Kole 7, Kirtan Dave 8, Prashant Kaushik 9, Mohammad Khairul Azhar Abdul Razab 10, Zulhazman Hamzah 3, Norazlina Mat Nawi 11
Affiliations 

Abstract

Background: Alzheimer’s disease (AD) is a prevalent, incurable, and chronic neurodegenerative condition characterized by the accumulation of amyloid-β protein (Aβ), disrupting various bodily systems. Despite the lack of a cure, phenolic compounds like cannabidiol (CBD), a non-psychoactive component of cannabis, have emerged as potential therapeutic agents for AD.

Objective: This systematic review explores the impact of different types of cannabidiol on AD, unveiling their neuroprotective mechanisms.

Methods: The research used PubMed, Scopus, and Web of Science databases with keywords like “Alzheimer’s disease” and “Cannabidiol.” Studies were evaluated based on title, abstract, and relevance to treating AD with CBD. No restrictions on research type or publication year. Excluded were hypothesis papers, reviews, books, unavailable articles, etc.

Results: Microsoft Excel identified 551 articles, with 92 included in the study, but only 22 were thoroughly evaluated. In-vivo and in-silico studies indicate that CBD may disrupt Aβ42, reduce pro-inflammatory molecule release, prevent reactive oxygen species formation, inhibit lipid oxidation, and counteract Aβ-induced increases in intracellular calcium, thereby protecting neurons from apoptosis.

Conclusions: In summary, the study indicates that CBD and its analogs reduce the production of Aβ42. Overall, these findings support the potential of CBD in alleviating the underlying pathology and symptoms associated with AD, underscoring the crucial need for further rigorous scientific investigation to elucidate the therapeutic applications and mechanisms of CBD in AD.

Keywords: Alzheimer’s disease; PPARγ; cannabidiol; systematic review; transient receptor potential channels.

PubMed Disclaimer

Figures

Figure 1.

Figure 2.

Figure 3.

References

    1. Koedam EL, Lauffer V, Van der Vlies AE, et al. Early-versus late-onset Alzheimer’s disease: more than age alone. J Alzheimers Dis 2010; 19: 1401–1408. – PubMed
    1. Zhang XX, Tian Y, Wang ZT, et al. The epidemiology of Alzheimer’s disease modifiable risk factors and prevention. J Alzheimers Dis 2021; 8: 313–321. – PubMed
    1. Mura T, Dartigues JF, Berr C. How many dementia cases in France and Europe? Alternative projections and scenarios 2010–2050. Eur J Neurol 2010; 17: 252–259. – PMC – PubMed
    1. Watt G, Karl T. In vivo evidence for therapeutic properties of cannabidiol (CBD) for Alzheimer’s disease. Front Pharmacol 2017; 8: 20. – PMC – PubMed
    1. Nichols E. Estimating the global mortality from Alzheimer’s disease and other dementias: a new method and results from the Global Burden of Disease Study 2019 . Doctoral Dissertation, University of Washington, 2019.

Publication types

LinkOut – more resources

Stay informed with the latest scientific insights, evidence-based independent research and discoveries on the ECS, cannabis medicine and more

Revolutionary Research on the ECS, cannabinoids and cannabis-based medicine for healthcare from a trusted nonprofit.

Leave a Reply